NVO Novo Nordisk A/S Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
04:54
Aug 29
Aug 29
Drugmakers anticipated strong sales when generic Ozempic launched in Indian pharmacies.
Drugmakers anticipated strong sales when generic Ozempic launched in Indian pharmacies, but the expected demand did not materialize.
16:10
Aug 27
Aug 27
Denmark raises its 2026 economic growth forecast for the fourth time.
Denmark raises its 2026 economic growth forecast for the fourth time, citing a bigger-than-expected boost from Novo Nordisk's new weight-loss pill.
06:20
Aug 27
Aug 27
Deutsche Bank downgrades Novo Nordisk to sell and cuts its price target to DKK 265 from DKK 290.
07:45
Aug 25
Aug 25
The author compares Pepsi to Novo Nordisk and suggests Coca-Cola as a better option.
The author compares Pepsi to Novo Nordisk and suggests Coca-Cola as a better option, but offers no explicit position or forward call.
LOW
20:17
Aug 21
Aug 21
Big Pharma faces oversight discount risk.
If Democrats take at least one chamber, they will use private-sector oversight as a second track, targeting companies with Trump ties and voter backlash. Big Pharma is directly in that Venn diagram, and Democrats are likely to call CEOs from companies like Novo Nordisk and Eli Lilly that signed drug pricing deals with the administration, so investors should put a discount into these stocks now.
HIGH
15:14
Aug 19
Aug 19
GLP-1 drugs like Ozempic/Wegovy are showing strong real-world adoption and increasing trust among GPs. Once insurers see these drugs reduce long-term healthcare costs, prescription volumes could scale massively — even if generics eventually appear. The market is mispricing Novo Nordisk’s long-term growth runway in weight-loss and metabolic disease. Slow insurance adoption, policy/pricing pressure, competition from Lilly and others, or clinical/safety setbacks could invalidate the thesis. No other actionable trade ideas in this post.
HIGH
14:52
Aug 19
Aug 19
Novo tests lower-dose Wegovy pills
Reports Novo Nordisk began testing lower doses of Wegovy weight-loss pills; clinical pipeline update without a directional recommendation.
MED
12:12
Aug 19
Aug 19
Novo Nordisk failed to hold market position
Notes Novo Nordisk was the largest player in the space but failed to hold up its market position.
LOW
09:26
Aug 19
Aug 19
Duopoly share-taker edge, NVO context
Speaker, an NVO investor, says duopoly share-takers usually outperform defenders and conservative management's negative impact can matter; no explicit NVO trade.
MED
07:55
Aug 19
Aug 19
Novo Nordisk begins a new study testing lower doses of its Wegovy pill to determine the minimum.
Novo Nordisk begins a new study testing lower doses of its Wegovy pill to determine the minimum effective dose for weight loss.
07:29
Aug 19
Aug 19
Novo Nordisk begins testing low-dose Wegovy pills in a new obesity study.
Novo Nordisk begins testing low-dose Wegovy pills in a new obesity study, expanding its weight-loss drug pipeline.
05:43
Aug 17
Aug 17
Novo Nordisk is down 42% over twelve months and trades at 11 times trailing earnings. The market is pricing in a permanent impairment due to US GLP-1 price resets, which is an overreaction. The extremely low valuation multiple for a dominant pharmaceutical company offers a strong margin of safety. GLP-1 price resets severely impact long-term profitability.
HIGH
20:00
Aug 16
Aug 16
Top comment recounts friends losing 80 lbs on Ozempic, ending with “Buying Novo Nordisk calls.” GLP-1 drugs appear culturally dominant, which could feed into NVO earnings and guidance. Buy NVO calls as a consumer-demand/GLP-1 theme trade. Only one direct comment, anecdotal rather than data-driven; valuation already reflects big GLP-1 expectations.
LOW
11:27
Aug 15
Aug 15
The author compiles a thread of user-recommended non-AI tickers as a research watchlist.
The author compiles a thread of user-recommended non-AI tickers as a research watchlist, explicitly noting he cannot guarantee they are all non-AI, so these are indexed as watch rather than trade ideas.
LOW
00:04
Aug 13
Aug 13
Novo pill runway makes stock too cheap
Doustdar says the oral GLP-1 launch is the best product launch in pharmaceutical history, with 1.5 million global patients on the pill, over 5 million US prescriptions, and 17% weight loss versus Lilly's 12%, implying strong company-specific growth from the pill.
HIGH
23:52
Aug 12
Aug 12
Massive pill adoption drives long-term company growth.
The Wegovy pill is experiencing the best product launch in pharmaceutical history, and while price reductions have temporarily masked revenue growth, the massive volume uptake and superior 17% weight loss profile position the company for decades of long-term success.
HIGH
21:25
Aug 12
Aug 12
The 109 billion dollar fund behind Novo Nordisk resumes investing after curbing allocations.
The 109 billion dollar fund behind Novo Nordisk resumes investing after curbing allocations earlier this year, focusing on attractively priced US opportunities.
18:15
Aug 12
Aug 12
Novo Holdings has resumed normal investment allocations after pausing earlier this year.
Novo Holdings has resumed normal investment allocations after pausing earlier this year, with CEO Kasim Kutay citing more attractive U.S. valuations and a stabilized outlook amid higher-for-longer rates.
10:45
Aug 12
Aug 12
JPMorgan, Deutsche Bank, Mizuho, Oppenheimer, Daiwa, Citizens, BTIG, William Blair, Jefferies.
JPMorgan, Deutsche Bank, Mizuho, Oppenheimer, Daiwa, Citizens, BTIG, William Blair, Jefferies, Berenberg, Raymond James, and China Renaissance issue multiple upgrades and downgrades with price target changes across a broad set of stocks.
12:06
Aug 11
Aug 11
Novo Nordisk announces its once-weekly insulin drug Awiqli is now available in the United.
Novo Nordisk announces its once-weekly insulin drug Awiqli is now available in the United States market.
16:16
Aug 10
Aug 10
Chamath presents a research deep dive on GLP-1 drugs' market expansion and indication cascade.
Chamath presents a research deep dive on GLP-1 drugs' market expansion and indication cascade, but frames it as educational content rather than a personal position or trade call.
12:14
Aug 10
Aug 10
NVO-AWS AI drug discovery partnership reported
Reports NVO and AWS formed a London co-innovation hub using AI to compress drug-target-to-first-dose timelines; no directional view stated.
LOW
08:50
Aug 10
Aug 10
Novo Nordisk is working to address the FDA's concerns regarding its Bloomington manufacturing.
Novo Nordisk is working to address the FDA's concerns regarding its Bloomington manufacturing plant.
16:04
Aug 07
Aug 07
Novo Nordisk cheap mean reversion
Novo Nordisk (NVO) has become attractively cheap after a decline, with strong fundamentals. He holds for a mean reversion target of $80.
MED
15:30
Aug 07
Aug 07
Investors are taking a pessimistic view toward Novo Nordisk as competition in next-generation.
Investors are taking a pessimistic view toward Novo Nordisk as competition in next-generation weight-loss drugs intensifies.
13:58
Aug 06
Aug 06
Semaglutide is one of the two molecules generating $71B in 2025, and the article's indication cascade suggests continued expansion into cardiovascular, kidney, sleep apnea, and potentially addiction.
Semaglutide is one of the two molecules generating $71B in 2025, and the article's indication cascade suggests continued expansion into cardiovascular, kidney, sleep apnea, and potentially addiction.
Risk: Tirzepatide has overtaken semaglutide as the best-selling drug, and next-generation obesity drugs could erode Novo's share.
05:05
Aug 06
Aug 06
European stocks trade subdued as HSBC and Novo Nordisk lead declines in the region's market.
European stocks trade subdued as HSBC and Novo Nordisk lead declines in the region's market session.
18:33
Aug 05
Aug 05
Lilly's obesity edge over Novo widens.
Eli Lilly is pulling ahead in the obesity-drug race due to a stronger pipeline (oral orforglipron), better marketing, and raised guidance, while Novo Nordisk's pipeline disappoints and its growth catalysts appear weaker, making the market favor Lilly over Novo.
HIGH
14:30
Aug 05
Aug 05
Novo Nordisk CEO Mike Doustdar reassured investors about rebuilding the pipeline and pledged.
Novo Nordisk CEO Mike Doustdar reassured investors about rebuilding the pipeline and pledged faster research after an upgraded 2026 outlook failed to lift sentiment.
14:00
Aug 05
Aug 05
Lilly management acknowledges Novo's oral GLP-1 launch in ex-US markets but claims its combined incretin portfolio share held steady, downplaying the competitive threat.
MED
About NVO Analyst Coverage
Buzzberg tracks NVO (Novo Nordisk A/S) across 53 sources. 146 bullish vs 7 bearish calls from 105 analysts. Sentiment: predominantly bullish (30%). 463 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Bloomberg, FirstSquawk, thebigberbowski.